New Directions in the Treatment of Basal Cell Carcinoma
Two dermatologists discuss how immune checkpoint inhibitors will change the way dermatologists manage skin cancer.
The Mainstream Patient: October 3
This week's edition of the Mainstream Patient features stories about recommended acne solutions from dermatologists, Latinx-owned beauty brands, the latest skin care trend of "skin energy," and more.
What's New on Dermatology Times®: October 3-7
Click to see a preview of what to expect this week.
The Weekly Roundup: September 26-30
ICYMI, this week we had stories about new study data on roflumilast foam for scalp and body psoriasis, dupilumab's FDA approval, the future of basal cell carcinoma treatment, and more.
What's Trending in Skin Care: September 2022
Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are trending for the month of September.
FDA Clears CellFX System for the Treatment of Sebaceous Hyperplasia
Pulse Biosciences' new technology will treat sebaceous hyperplasia patients with Fitzpatrick skin types I-III.
New Study Data of Roflumilast Foam for Scalp and Body Psoriasis
Arcutis Biotherapeutics announced positive results from the ARRECTOR phase 3 trial.
The Mainstream Patient: September 26
This week's edition of the Mainstream Patient features stories about the best sunscreens for fall, Botox for excessive sweating, Brad Pitt's entrance into the skin care industry, and more.
The Weekly Roundup: September 19-23
ICYMI, this week we had stories about the role of precision medicine for managing melanoma, a debridement drug for severe pediatric burns, roflumilast cream phase 3 results, and an exclusive KOL interview.
The Value of Roflumilast Cream for Plaque Psoriasis
Roflumilast cream adds a much-needed element of simplicity for psoriasis patients and their dermatologists.
JAMA Publishes Roflumilast Cream Phase 3 Trial Results for Plaque Psoriasis
Arcutis Biotherapeutics’ roflumilast cream showed higher efficacy compared to vehicle in two phase 3 studies.
EMA Accepts Application for Extended Indication of NexoBrid for Severe Pediatric Burns
MediWound’s debridement drug will provide a safer non-surgical alternative to severe thermal burns for pediatric patients.
The Mainstream Patient: September 19
This week's edition of the Mainstream Patient features stories about skin cycling, skin care routines from dermatologists, upcoming nail trends, body care, and more.
The Weekly Roundup: September 12-16
ICYMI, this week we had stories about products to help manage acne, a case study on pediatric vitiligo, data results from a hidradenitis suppurativa clinical trial, BCC management, and more.
Adjuvant Treatment With Nivolumab Shows Positive Results in Phase 3 Trial
Bristol Myers Squibb’s nivolumab shows potential for treatment in earlier stages of melanoma.
Positive Results from 2 Novartis Trials for HS Treatment
SUNSHINE and SUNRISE trials showed superior efficacy over the placebo.
The Mainstream Patient: September 12
This week's edition of the Mainstream Patient features stories about the best retinol creams, the Blue Beauty movement, lip blushing, and more.
A Fresh Look at Alopecia Areata
Taking a deep dive into alopecia areata allows for a better understanding of the cells that are responsible for disease development.
Deucravacitinib Approved by FDA for Treatment of Psoriasis
Deucravacitinib offers new hope for those with moderate-to-severe plaque psoriasis.
Evidence of Cumulative Life Course Impairment in Hidradenitis Suppurativa
Study data was presented at EADV 2022 regarding socioeconomic status related to HS.
The Role of Nonprescription Products in the Management of Acne
Joshua Zeichner, MD, and Mona Gohara, MD, discuss adherence issues and adverse effects related to topical treatments for acne vulgaris.
Timber Pharmaceuticals Presents CI Study Data at EADV Congress
TMB-001 showed positive results in the reduction of congenital ichthyosis severity in a phase 2b CONTROL study.
FDA Approves DaxibotulinumtoxinA for Injection for Glabellar Lines
DaxibotulinumtoxinA for Injection will provide long-lasting results with fewer injection treatments over time.
Updates on Mental Health and Psoriasis at EADV 2022
The relationship between mental health and psoriasis was discussed at EADV Congress 2022 in Milan, Italy.
The Mainstream Patient: September 5
This week's edition of the Mainstream Patient features stories about facial exfoliators, skin-picking disorders, hydra-facials, and more.
The Weekly Roundup: August 29-September 2
ICYMI, this week we had stories about non-prescription acne treatments, clinical study results, pediatric atopic dermatitis, and the EADV 2022 Congress.
FDA Approves Spesolimab-Sbzo Injection for GPP Flares
Boehringer Ingelheim’s first treatment option for adults will help manage burdensome flares.
FDA Grants Extended Clearance of Avéli for the Reduction of Cellulite
Revelle Aesthetics’ cellulite reduction device helps address frustrating aesthetic concerns.
Imsidolimab Development for HS Discontinued
AnaptysBio will refocus R&D efforts on its immune cell modulator pipeline.
What's Trending in Skin Care: August 2022
Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are trending for the month of August.